PPARG and type 2 diabetes mellitus: Though PPARγ agonist Rosiglitazone has been used for treatment of type 2 diabetes in clinic, whether the protective effects of PPARγ detected in the animal model could be extrapolated to the clinical application is subject to the future clinical trials.